CNP and mucopolysaccharidosis: Furthermore, a Phase I/II clinical trial of the CNP analog in MPS IVA and VI patients has been initiated to explore further these therapeutic possibilities (ClinicalTrials.gov ID: NCT05845749) and inform the scientific community about the latest developments in MPS research.